ipilimumab
Aliases
Yervoy
8 clinical trials
1 product
212 abstracts
14 indications
Indication
Pancreatic CancerIndication
MesotheliomaIndication
CancerIndication
LungIndication
Lung cancerIndication
Mesothelioma, Malignant, PleuralIndication
MelanomaIndication
Stage IIIA MelanomaIndication
Stage III MelanomaIndication
Stage IV melanomaIndication
Metastatic MelanomaIndication
cancerIndication
Non-Small Cell LungIndication
Uveal melanomaClinical trial
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First LineStatus: Recruiting, Estimated PCD: 2024-07-01
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,
Abstract
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609).Org: University of Washington/Fred Hutchinson Cancer Center and SWOG Statistics and Data Management Center, Seattle, WA, UC San Diego Moores Cancer Center, La Jolla, CA, Northwestern University, Chicago, IL, National Cancer Institute/National Institutes of Health, Bethesda, MD, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
A phase I trial on the intra- and post-operative intracranial administration of ipilimumab and nivolumab in patients with recurrent high-grade glioma.Org: Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), CellCarta,
Abstract
Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.Org: Department of Gastroenterology, Hepatology, and Nutrition University of Texas MD Anderson Cancer Center,
Abstract
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Org: Gustave Roussy Cancer Campus, EORTC Headquarters, Université Clermont Auvergne, Dermato-Oncology and CIC AP-HP Hôpital Saint Louis, Université de Versailles-Saint Quentin en Yvelines,
Abstract
Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702—Survival results.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Breast Cancer Trials - Australia and New Zealand, NHMRC Clinical Trials Centre, Monash Health, Bentleigh East, VIC, Australia, Macarthur Cancer Therapy Center,
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Org: Department of Interventional Radiology,
Abstract
SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.Org: Toledo, Spain, Santiago De Compostela, Spain, Sevilla, Spain, Oviedo, Spain, Huelva, Spain,
Abstract
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.Org: University of Bonn, University of Frankfurt, University of Würzburg, MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbH, Hospital Cologne-Merheim,
Abstract
Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.Org: Macquarie University, Chris O'Brien Lifehouse, Melanoma Institute Australia, Netherlands Cancer Institute (NKI-AVL),
Abstract
Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitors by investigation of CD8+ immune infiltrate with [89Zr] crefmirlimab berdoxam PET.Org: Department of Dermatology, Eberhard Karls University of Tübingen, Department of Dermatology, University Hospital Tuebingen, Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen,
Abstract
Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial.Org: University of Sao Paulo, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.Org: BC Cancer-Vancouver Centre, University of British Columbia,
Abstract
Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.Org: Netherlands Cancer Institute, Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, University Medical Center Utrecht,
Abstract
Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients.Org: Baylor University Medical Center, Dallas, TX,
Abstract
Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM II trial).Org: University of Gothenburg, Skane University Hospital Comprehensive Cancer Center, University Hospital of Umeå,
Abstract
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.Org: LungenClinic, Grosshansdorf, Germany, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, L’institut du Thorax, Nantes, France, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, Hospital Universitario La Fe, Valencia, Spain,
Abstract
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.Org: Departments of Cutaneous Oncology and Immunology,
Abstract
Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.Org: Melanoma Medical Oncology Department, Rheumatology and Clinical Immunology Section,
Abstract
First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.Org: Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Rogel Comprehensive Cancer Center, Ann Arbor, MI, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, City of Hope Comprehensive Cancer Center, Duarte, CA, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Campus Biomedico, Roma, Italy, University Hospital of Parma, Fontevivo, Italy, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA,
Abstract
A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.Org: Huntsman Cancer Institute and Department of Neurosurgery, University of Kentucky Markey Cancer Center, University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute National Institutes of Health, Melanoma Program UPMC Hillman Cancer Center,
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Abstract
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,
Abstract
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.Org: 1440 Foundation,
Abstract
Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).Org: Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,
Abstract
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.Org: Bucks, Nottingham University Hospitals NHS Trust, Churchill Hospital, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust,
Abstract
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587).Org: University of California, San Diego (UCSD), Hematology/Oncology, Weill Cornell Medicine, Pelotonia Institute for Immuno-Oncology and Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center,
Abstract
Triage of advanced cervical cancer through immunotherapy induction (TRACTION).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.Org: Frontier Science Foundation - Hellas, Hospital Virgen De La Salud, Hôpital Arnaud de Villeneuve, St. James's Hospital and Trinity College Dublin, Cancer Molecular Diagnostics,
Abstract
Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center.Org: Chardon, OH, Cancer Informatics,
Abstract
The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).Org: Bionutrition Research Core,
Abstract
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.Org: Maria Skłodowska-Curie National Institute of Oncology Center, Warsaw, Poland, University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, Gustave Roussy and Paris-Saclay University, Villejuif, France, Veneto Institute of Oncology, IOV–IRCCS, Veneto, Italy, Hospital General Universitario Gregorio Marañón and CIBERONC, Madrid, Spain,
Abstract
The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.Org: The Netherlands Cancer Institute, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Cancer Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center,
Abstract
Continuous intrathecal infusion of nivolumab in advanced melanoma with leptomeningeal disease.Org: UFR Médecine Paris Nord, Neurosurgery Department, Assistance Publique hôpitaux de Paris, Beaujon Hospital, Mutimodal imaging lab (Biomaps) Université Paris Saclay/CEA/CNRS UMR9011/INSERM UMR1281,
Abstract
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.Org: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University,
Abstract
Comparison of ICI plus chemotherapy or ipilimumab plus nivolumab based therapy for patients with NSCLC with TPS (1-49%): TOPGAN2023-01.Org: Hirosaki University, Japanese Foundation for Cancer Research, Kanazawa University Hospital, University of Yamanashi, The Jikei University Daisan Hospital,
Abstract
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.Org: Melanoma Research Alliance,
Abstract
With eyes on the future: Prospective evaluation of immune-related adverse events in patients with lung cancer.Org: Hospital das Clinicas UFMG,
Abstract
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).Org: Croix-Rousse Hospital, Service d’Hépato-Gastroentérologie, Hôpital Purpan, FFCD - INSERM U1231, Hopital Duchenne,
Abstract
The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Georgetown-Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.Org: Elekta - Kaiku Health, Antoni van Leeuwenhoek/Netherlands Cancer Institute (NKI), Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney,
Abstract
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.Org: Université Paris Cité, AP-HP Dermato-Oncology and CIC, Cancer Institute APHP, Aix-Marseille University, CEPCM, and CHU de La Timone APHM, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron Hospital Medical Oncology Department, Leeds Institute of Medical Research at St. James’s, University of Leeds, Jonsson Comprehensive Cancer Center, University of California Los Angeles,
Abstract
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.Org: AZ Sint-Augustinus,
Abstract
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,
Abstract
Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.Org: Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Unidade Local de Saúde de Santo António,
Abstract
Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy.Org: Stanford Cancer Institute, Stanford Cancer Center,
Abstract
A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.Org: Inst for Clinical Evaluative Sci,
Abstract
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,
Abstract
Overlapping and non-overlapping indications for checkpoint inhibitors in the US.Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.Org: Johannes-Gutenberg University Clinic, Mainz, Germany, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile, Fundacion Arturo López Pérez, Providencia, Chile, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland,
Abstract
Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy.Org: The Royal Marsden Hospital, The Royal Marsden Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, Melanoma Institute Australia,
Abstract
Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Sarcoma Oncology Center, City of Hope Comprehensive Cancer Center, UCLA David Geffen School of Medicine,
Abstract
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,
Abstract
Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).Org: University of Miami Bascom Palmer Eye Institute,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,
Abstract
The pan-cancer landscape of SMARCA4 and SMARCB1 alterations in a large cohort of Chinese patients.Org: General Hospital of Central Theater Command, Suzhou, China,
Abstract
Nivolumab monotherapy and associations in the treatment of advanced unresectable biliary tract cancer (BTC): A systematic review and meta-analysis.Org: Canoas Health Office, Canoas, Brazil, Federal University of Pelotas, Belo Horizonte, Brazil,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Induction immunotherapy-based regimens followed by palliative CCRT may lead to conversion surgery in selected patients and boost survival for stage IV ESCC.Org: National Taiwan University Hospital Yunlin Branch, Yunlin, Yun-lin Branch, Yunlin County,
Abstract
Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study.Org: Division of Cardiovascular Imaging, St. Francis Hospital & Heart Center, DeMatteis Cardiovascular Institute of St. Francis Hospital, Cardio-Oncology Service, Cardiology Division,
Abstract
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.Org: Guys' and St. Thomas' NHS Foundation Trust, Southampton Experimental Cancer Medicine Centre, University of Southampton, Velindre Cancer Centre, Velindre University NHS Trust, Cancer Research UK & UCL Cancer Trials Centre, University College London, Department of Laboratory Medicine and Pathology, University of Washington,
Abstract
Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade.Org: Penn Medicine Abramson Cancer Center,
Abstract
Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,
Abstract
Quality of life outcomes in patients with resectable dedifferentiated liposarcoma treated with neoadjuvant immunotherapy.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Effect of combinatorial immune checkpoint blockade on myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β, and interleukin-6: Biochemical implications in cardio-immuno-oncology.Org: Division of Cardiology, Istituto Nazionale Tumori –IRCCS- Fondazione G. Pascale, Naples, Italy, IRCCS Fondazione G. Pascale, Napoli, Italy, Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar Di Valpolicella, Italy,
Clinical trial
Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaStatus: Terminated, Estimated PCD: 2021-12-06
Clinical trial
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)Status: Active (not recruiting), Estimated PCD: 2025-03-15
Clinical trial
A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV MelanomaStatus: Terminated, Estimated PCD: 2020-01-27
Clinical trial
A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma)Status: Terminated, Estimated PCD: 2022-08-03
Clinical trial
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLCStatus: Terminated, Estimated PCD: 2021-10-22
Clinical trial
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaStatus: Recruiting, Estimated PCD: 2025-08-01
Abstract
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.Org: Centre Léon Bérard, School of Medicine, Showa University, Centre François Baclesse, Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Claudius Regaud, IUCT-Oncopole, CRCT, lnserm, Toulouse, France,
Abstract
Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.Org: Netherlands Cancer Institute (NKI-AVL), Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, The Netherlands Cancer Institute, University Medical Cancer Center Utrecht, Netherlands Cancer Institute,
Abstract
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,
Abstract
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).Org: UC San Diego Moores Cancer Center, National Cancer Institute/National Institutes of Health, Medical College of Wisconsin and WIN Consortium, Fred Hutchinson Cancer Center, Northwestern University,
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.Org: Melanoma Institute Australia, Mater and Royal North Shore Hospitals, Leiden University Medical Center, University Medical Center Utrecht, University Medical Center Groningen,
Abstract
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,
Abstract
Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).Org: Memorial Sloan Kettering Cancer Center, Hartford Health Center Cancer Institute, Lehigh Valley Topper Cancer Institute, Weill Cornell Medical College University,
Abstract
Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, University of Texas Southwestern Medical Center, Division of Digestive and Liver Diseases, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).Org: The Translational Genomics Research Institute (TGen), City of Hope Comprehensive Cancer Center, Centro de Cancer de Brasilia, Grupo Oncoclinicas, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,
Abstract
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.Org: Netherlands Cancer Institute, Melanoma Institute Australia, Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Netherlands Cancer Institute (NKI-AVL),
Abstract
Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.Org: Frank H Netter MD School of Medicine, Dana-Farber Cancer Institute, Quinnipiac University, Dana-Farber Cancer Institute and Harvard Medical School,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.Org: University College Hospital-London, The Christie Hospital NHS Foundation Trust, Guy's Hospital, Western General Hospital, Addenbrooke's Hospital,
Abstract
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.Org: UPR "Chronotherapy, Cancers and Transplantation", Paris-Saclay University, Villejuif, France, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom, Department of Thoracic and Medical Oncology, Avicenne AP-HP, Université Sorbonne Paris Nord, Bobigny, France,
Abstract
Immune-related adrenal insufficiency: A single center retrospective analysis.Org: Moscow Clinical Scientific Center Named after Loginov A.F., Moscow Clinical Scientific Center named after A.S. Loginov, Loginov Moscow Clinical Scientific Center,
Abstract
The study of immune-related adverse events in a community-based centre.Org: BronxCare Health System, Bronx-Lebanon Hospital Center, BronxCare Mount Sinai Comprehensive Cancer Care,
Abstract
Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada,
Abstract
Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.Org: University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hämatologisch-Onkologische Praxis Eppendorf (HOPE) and University Cancer Center Hamburg (UCCH), Department of Internal Medicine IV, University Hospital Halle, Hematology Oncology Practice Eppendorf,
Abstract
Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.Org: Saint John's Cancer Institute, Pacifica Neuroscience Institute, Pacific Neuroscience Institute and Saint John’s Cancer Institute at Providence Saint John’s Health Center, Saint John's Health Center,
Abstract
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.Org: Hackensack University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Karmanos Cancer Institute, The Sarah Cannon Research Institute, Stephenson Cancer Center,
Abstract
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,
Abstract
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.Org: Johns Hopkins Kimmel Cancer Center, Regeneron Pharmaceuticals, Inc., Department of Nuclear Medicine Zürich, University Hospital of Zürich, Department of Medical Oncology, Başkent University, High Technology Medical Centre, University Clinic,
Abstract
SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Central University Hospital of Asturias, Hospital Juan Ramón Jiménez de Huelva, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).Org: Massachusetts General Hospital, UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
Multisystem immune-related adverse events from dual agent immunotherapy use.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario Institute for Cancer Research, Toronto, ON, Canada, Oncotelic,
Abstract
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,
Abstract
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.Org: University of Calgary, Texas Oncology PA, Ipsen, Ontada, McMaster University and Juravinski Cancer Centre,
Abstract
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).Org: University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, University of Pittsburgh Department of Otolaryngology,
Abstract
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, Moffitt Cancer Center, Tampa, FL,
Abstract
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.Org: Università degli Studi di Milano, Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, University of Turin, Candiolo Cancer Institute-FPO, IRCCS,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.Org: Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Applied Bioinformatics Laboratories, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Dermatology,
Abstract
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, Barbara Ann Karmanos Cancer Institute, Indiana University Simon Comprehensive Cancer Center,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, UC San Diego Moores Cancer Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, Loma Linda University Department of Radiation Technology,
Abstract
Molecular subtypes from comprehensive clustering from multi-omics dataset to predict the therapeutic efficacy of immunotherapeutic agent-based treatments in advanced hepatocellular carcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, CHA University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Medical Oncology Group,
Abstract
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.Org: Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Johannes-Gutenberg University Clinic, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Fundacion Arturo López Pérez,
Abstract
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.Org: University of Texas MD Anderson Cancer Center, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Txinno Bioscience, University of Virginia, Charlottesville, VA, USA, Charlottesville, VA,
Abstract
Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.Org: Faculty of Biology, Technion-Israel Institute of Technology, Carelon Digital Platforms,
Abstract
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.Org: Yale University School of Medicine, Ocean Genomics, Yale University Dept of Pathology, Yale School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health Division of Occupational Health and Safety, Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI,
Abstract
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).Org: City of Hope Comprehensive Cancer Center, Quantitative Medicine and Systems Biology Division, Translational Genomics Research Institute (TGen North), Integrated Cancer Genomics Division, Yale University School of Medicine,
Abstract
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Columbia University Irving Medical Center, New York, NY, USA, Yale School of Public Health,
Abstract
Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.Org: Mayo Clinic, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,
Abstract
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.Org: University of Kentucky, Lexington, KY,
Abstract
Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).Org: James P. Wilmot Cancer Center/URMC - JPWCC, Memorial Sloan Kettering Cancer Center,
Abstract
PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.Org: AdventHealth Cancer Institute, Orlando, FL, James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, University of California Davis Comprehensive Cancer Center, OncoC4,
Abstract
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Johns Hopkins University Department of Rheumatology, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD,
Abstract
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.Org: Imperial College, Imperial College London, Imperial College, St Mary's Campus, Imperial College Healthcare NHS Trust, Barts and The London HPB Centre,
Abstract
The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB).Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas at MD Anderson Cancer Center,
Abstract
FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,
Abstract
Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.Org: Georgetown - Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, Medstar Franklin Square Medical Center, Georgetown Lombardi Comprehensive Cancer Center,
Abstract
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,
Abstract
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,
Abstract
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.Org: New York University School of Medicine, Bristol Myers Squibb, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,
Abstract
Factors associated with myocarditis in patients with cancer treated with immune checkpoint inhibitors.Org: Bristol Myers Squibb, Mayo Clinic,
Abstract
First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, Dana-Farber Cancer Institute, Department of Medical Oncology, University of California San Diego,
Abstract
Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,
Abstract
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas - M. D. Anderson Cancer Center, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center,
Abstract
Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.Org: University of Manitoba, CancerCare Manitoba,
Abstract
Safety of checkpoint inhibitors in older patients with genitourinary cancers.Org: University of Florida/UF Health Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.Org: Houston Methodist Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Retina Consultants of Texas,
Abstract
Serum cytokines and autoantibodies to GM-CSF and immune-related colitis in ipilimumab-treated patients with cancer.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Hospital-Breast Medical Oncology, Memorial Sloan Kettering Cancer Center, Precision Immunology Institute, The Tisch Cancer Institute at Mount Sinai Health System,
Abstract
Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.Org: Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI, Nihon Medi-Physics, Hospital Sírio-Libanês,
Abstract
Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.Org: Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Cancer and Wellness Center,
Abstract
Immune checkpoint inhibition in locally advanced rectal adenocarcinoma at Mayo Clinic.Org: Mayo Clinic, Jacksonville, FL,
Abstract
Immunotherapy-related toxicities: A retrospective analysis of barriers to prompt detection and initiation of treatment in renal cell carcinoma.Org: TCU School of Medicine, UTSW Harold C Simmons Comprehensive Cancer Center,
Abstract
[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.Org: The Netherlands Cancer Institute (NKI), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Division of Medical Oncology, Netherlands Cancer Institute, Department of Head and Neck Surgical Oncology, Netherlands Cancer Institute (NKI-AVL),
Abstract
Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.Org: Mayo Clinic in Arizona, Phoenix Tissue Repair, Azidus Brasil, Mayo Clinic Arizona, Phoenix, AZ, Scottsdale,
Abstract
The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.Org: Princess Margaret Cancer Centre, ICES, Ontario Health (Cancer Care Ontario), Princess Margaret - University Health Network, University Health Network,
Abstract
The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.Org: Hull University Teaching Hospitals NHS Trust, University of Leeds, Royal Cornwall Hospital NHS Trust,
Abstract
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,
Abstract
A phase Ib study of endogenous T cell therapy using SLC45A2-specific CD8 T cells for patients with metastatic uveal melanoma.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, MD Anderson Cancer Center,
Abstract
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.Org: Netherlands Cancer Institute, Division of Psychosocial Oncology and Epidemiology, Core Facility Molecular Pathology and Biobanking, Melanoma Institute Australia, The University of Sydney,
Abstract
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Moffitt Cancer Center, National Cancer Institute/National Institutes of Health, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center,
Abstract
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, São Paulo, Brazil, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil, Beneficencia Portuguesa, AC Camargo Cancer Center,
Abstract
Long-term follow-up results of ipilimumab and nivolumab for the treatment of mismatch repair deficient locally advanced rectal cancer.Org: University of Wisconsin Carbone Cancer Center, Madison, WI,
Abstract
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
A prediction model for response to immune checkpoint inhibition in advanced melanoma.Org: University Medical Center Utrecht, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, VU University Medical Center, Isala Oncology Center, University Medical Center of Utrecht,
Abstract
A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden,
Abstract
The association between body mass index and immune checkpoint inhibitors outcomes in melanoma: Results from real-world data.Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center,
Abstract
Impact of antibiotics on survival outcomes and risk of gastritis/colitis in patients with advanced-stage melanoma receiving anti-PD-1 therapy.Org: University of Wisconsin Health, University of Wisconsin-Madison Carbone Cancer Center, University of Wisconsin, Madison, University of Wisconsin - Carbone Cancer Center,
Abstract
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.Org: UPMC Hillman Cancer Center, Clear Lake Oncology, Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL, Massachusetts General Hospital,
Abstract
Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,
Abstract
Immune-related hypophysitis: An analysis of a heterogeneous entity.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).Org: Department of Medical Oncology, University of California San Diego, San Diego, CA, St. Martin’s University, Lacey, WA, Northwestern, Chicago, IL, University of Chicago Department of Medicine, Chicago, IL, University of Kansas Cancer Center, Westwood, KS, University of Pittsburgh Medical Center Oncology Group, Beaver, PA, University of Florida Health Cancer Center, Gainesville, FL, University of Chicago, Chicago, IL, Fred Hutchinson Cancer Research Center, Seattle, WA, SWOG Data Operations Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, National Cancer Institute, Bethesda, MD, National Cancer Institute/National Institutes of Health, Bethesda, MD, OHSU Knight Cancer Institute, Portland, OR, Oregon Health and Science University, Departments of Medicine and Pediatrics/ Kn, Portland, OR, Medical College of Wisconsin and WIN Consortium, Milwaukee, WI,
Abstract
IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Harbin Medical University Cancer Hospital, Henan Cancer Hospital, Peking University First Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China,
Abstract
Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database.Org: Rochester General Hospital, Rochester, NY, Patan Academy of Health Sciences, Kathmandu, Nepal, Kathmandu, Nepal, University at Buffalo Jacobs School of Medicine and Biomedical Sciences,
Abstract
Real world data on immunotherapeutic outcomes in solid tumours.Org: The Brunei Cancer Center, The Brunei Cancer Centre,
Abstract
Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela.Org: Centro Medico Docente La Trinidad, Caracas, Venezuela (Bolivarian Republic of), Beth Israel Deaconess Medical Center, Boston, MA, Advocate Aurora Health, Chicago, IL, Centro Medico Docente la Trinidad, Caracas, Miranda, Venezuela (Bolivarian Republic of),
Abstract
A functional immuno-oncology (IO) assay to assess patient response to immunotherapeutics in metastatic disease.Org: Xilis, Inc., Xilis Inc., Xilis,
Abstract
CCT6A and triple-negative breast cancer metastasis: Activating the AKT/MDM2/P53 pathway.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Fudan University (Xiamen Branch), Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Breast and Urinary Oncology,
Abstract
Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.Org: UC Irvine, University of California Irvine, UCI Health,
Abstract
Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.Org: Harlem Hospital Center, New York Oncology Hematology PC,
Abstract
Retreatment with nivolumab and ipilimumab with or without chemotherapy in patients with metastatic non-small cell lung cancer after progression on immune checkpoint inhibitor therapy.Org: Lausanne University Hospital, Geneva University Hospitals,
Abstract
Evaluating novel imaging-based mathematical modeling prediction of immunotherapy response by individual melanoma brain metastasis and patient prognosis.Org: University of Texas MD Anderson Cancer Center, Houston, TX, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Queensland Health,
Abstract
Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.Org: HIA SAINTE ANNE, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.Org: Centre for Cancer Biomarkers CCBIO, University of Bergen, Dept. of Urology, Haukeland University Hospital, Dept. of Pathology,
Abstract
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,
Abstract
Patterns of care delivery and outcomes in patients with melanoma brain metastases treated with ipilimumab/nivolumab.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke Cancer Institute, Duke Medical Center, Department of Radiation Oncology, Duke University Medical Center, Durham, NC,
Abstract
Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab.Org: Maria Sklodowska-Curie National Research Institute of Oncology, Heliodor Swiecicki Clinical Hospital, Greater Poland Cancer Centre, Mossakowski Medical Research Centre, Polish Academy of Sciences,
Abstract
Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,
Abstract
Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,
Abstract
Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs).Org: University of Washington School of Medicine, Vanderbilt University Medical Center, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Emory University, Atlanta, GA, USA,
Abstract
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.Org: Pfizer Inc., London, United Kingdom, Kirkland, QC, Canada, Pfizer, Inc., Cambridge, MA, Pfizer,
Abstract
Incidence of immune checkpoint inhibitor induced myocarditis in patients with mesothelioma from a regional tertiary cancer centre covering a patient population of 2.6 million.Org: Clatterbridge Cancer Centre NHS FT, Liverpool Hospital Anatomical Pathology, Wirral,
Abstract
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.Org: Johns Hopkins Hospital, Columbia University Irving Medical Center, New York, NY, USA, Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, University of Massachusetts Memorial Medical Center, University of Southern California, Norris Comprehensive Cancer Center,
Abstract
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,
Abstract
Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,
Abstract
Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma.Org: Levine Cancer Institute, Atrium Health Carolinas Medical Center, Department of Cancer Biostatistics,
Abstract
Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Biotherapy Center,
Abstract
Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing.Org: Ourotech Ltd t/a Pear Bio, Royal Free London NHS Foundation Trust,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.Org: Hôpital Européen Georges-Pompidou, Paris, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, University Hospital 12 de Octubre, LMU Munich,
Abstract
Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.Org: University Hospitals Cleveland Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,
Abstract
Eosinophilia in patients with melanoma under treatment with immune checkpoint inhibitor-based regimens.Org: First Department of Internal Medicine, Hematology and Oncology Unit, Athens, Greece, First Department of Internal Medicine, Laiko Hospital, Athens, Greece, First Department of Internal Medicine, Laiko Hospital, Athens, Greece, Athens, Greece, First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece,
Abstract
Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliero-Universitaria Pisana, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience.Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SOLTI Cancer Research Group, Hospital Vall d'Hebron,
Abstract
Retrospective analysis of NUT carcinoma: The Northwestern experience.Org: Northwestern Medicine Cancer Center Warrenville, Northwestern University-Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Abstract
Relationship of adverse events after combined immunotherapy and treatment outcomes in patients with advanced melanoma: A multicenter experience in Poland.Org: The Maria Skłodowska-Curie National Research Institute of Oncology, Kraków Branch, Oncology Center - Prof Franciszek Lukaszczyk Memorial Hospital, Frederic Chopin Provincial Hospital No.1, Specialist Oncological Hospital NU-MED LCC-Chemotherapy Subward, Medical University of Lodz, Lodz, Poland,
Abstract
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.Org: Arnie Charbonneau Cancer Research Institute, University of Calgary, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Alberta, Tom Baker Cancer Centre,